Status | In progress |
Technology type | Medicine |
Decision | Selected |
Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
Further information | Awaiting development |
Process | STA Standard |
ID number | 6327 |
Provisional Schedule
Expected publication | 12 June 2024 |
Project Team
Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
External Assessment Group | Kleijnen Systematic Reviews Ltd |
Stakeholders
Companies sponsors | Pfizer |
Others | Department of Health & Social Care |
NHS England | |
Patient carer groups | Cardiomyopathy UK |
UK ATTR Amyloidosis Patients’ Association | |
Professional groups | British Cardiovascular Society |
British Society for Heart Failure | |
National Amyloidosis Centre | |
Royal College of Physicians | |
UK Clinical Pharmacy Association | |
Comparator companies | Akcea Therapeutics UK (inotersen) - CAU not returned, not participating |
Alnylam Pharmaceuticals (patisiran, | |
vutrisiran) | |
General commentators | All Wales Therapeutics and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare Products Regulatory Agency | |
Scottish Medicines Consortium | |
Welsh Government | |
Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
03 April 2024 | Committee meeting: 2 |
27 February 2024 - 19 March 2024 | Draft guidance |
06 February 2024 | Committee meeting: 1 |
01 September 2023 | Invitation to participate |
01 September 2023 | In progress. Invitation to Participate |
18 August 2023 - 25 August 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
08 August 2023 | Awaiting development |
For further information on our processes and methods, please see our CHTE processes and methods manual